Results 71 to 80 of about 749,314 (382)
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation [PDF]
Leukemia. 24 (2010) 460-6, 2010 Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to an adherent monocytic phenotype ...
arxiv +1 more source
Molecular Oncology, EarlyView.Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa +13 more
wiley +1 more source
Low expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia
Tumor Biology, 2017 Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive.
Jing-dong Zhou +10 more
doaj +1 more source
Clinical proteomics of myeloid leukemia [PDF]
Genome Medicine, 2010 Myeloid leukemias are a heterogeneous group of diseases originating from bone marrow myeloid progenitor cells. Patients with myeloid leukemias can achieve long-term survival through targeted therapy, cure after intensive chemotherapy or short-term survival because of highly chemoresistant disease.
Rakel Brendsdal Forthun +6 more
openaire +3 more sources
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, EarlyView.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source
Granular B lymphoblastic leukemia
, 2023 American Journal of Hematology, Volume 98, Issue 1, Page 210-211, January 2023.
Biswadip Hazarika, Barbara J. Bain
wiley +1 more source
Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]
Anais Brasileiros de Dermatologia, 2017 : Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites.
Erica Rodrigues de Araujo Vasconcelos +2 more
doaj +1 more source
Myeloid leukemia after hematotoxins. [PDF]
Environmental Health Perspectives, 1996 One of the most serious consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can now be distinguished. Classic therapy-related myeloid leukemia typically occurs 5 to 7 years after exposure to alkylating agents and/or irradiation, has a myelodysplastic phase with ...
Richard A. Larson +3 more
openaire +2 more sources
Molecular Oncology, EarlyView.CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar +4 more
wiley +1 more source
New England Journal of Medicine, 2003 BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien +24 more
semanticscholar +1 more source